2023 ASCO Conference: The Latest Cancer Treatment and Research

The discussion wasn’t “radiation is bad.” It was “radiation is powerful, and we should use it precisely.”
That nuanceusing intensive treatments when they truly add benefit, and sparing them when they don’twas peak ASCO 2023 energy.

Brain tumors: Targeted therapy that can delay chemo and radiation (INDIGO)

Another standout: the INDIGO trial in grade 2 glioma with IDH1 or IDH2 mutations. Instead of immediately moving to radiation and chemotherapy
(which can have significant long-term effects), INDIGO evaluated a targeted IDH inhibitor, vorasidenib.

The key idea was patient-centered in the most practical way possible:
if a targeted pill can slow tumor growth and delay the need for more toxic therapy, that can preserve quality of lifeespecially in a population
that may otherwise live with a slow-growing tumor for years.

In the ASCO 2023 conversation, vorasidenib wasn’t framed as “magic.” It was framed as a smarter sequencing strategy:
use biology to buy time, reduce harm, and keep future options open.

Lung cancer: Two different “early-stage” breakthroughstargeted therapy and perioperative immunotherapy

Lung cancer research at ASCO 2023 delivered one of the clearest snapshots of modern oncology’s direction:
personalize treatment up front, and move powerful therapies earlier when evidence supports it.

ADAURA (overall survival): Updates from ADAURA strengthened the case for adjuvant osimertinib in resected EGFR-mutated
non–small cell lung cancer. The overall survival results added weight to the argument that targeted therapy after surgery can meaningfully change the
long-term trajectory for selected patients.

KEYNOTE-671: On the immunotherapy side, KEYNOTE-671 evaluated a perioperative strategy using pembrolizumab plus
platinum-based chemotherapy before surgery and continuing pembrolizumab after surgery in resectable NSCLC.
The attention here wasn’t just about statisticsit was about the strategy: shrinking disease early, improving surgical outcomes, and reducing recurrence risk
by keeping the immune system engaged across the surgical “before-and-after.”

Put together, these studies captured the new reality: early-stage cancer isn’t automatically “simple.”
The best plan may include surgery plus a biologically targeted layerchosen based on tumor genetics and risk.

Breast cancer: CDK4/6 inhibitors pushing into the adjuvant setting (NATALEE)

Breast cancer research at ASCO often feels like drinking from a firehoseexcept the firehose is also somehow a spreadsheet.
One of the most-discussed studies in 2023 was NATALEE, which evaluated adding ribociclib (a CDK4/6 inhibitor) to
endocrine therapy for a broad population of patients with HR-positive/HER2-negative early breast cancer.

The central question: can we reduce recurrence risk by extending a therapy class that’s already proven in advanced disease into earlier-stage care?
NATALEE’s results supported an improvement in invasive disease–free survival, sparking serious conversation about future standardsalong with the
very patient-centered follow-up question: how do we balance benefit with side effects, monitoring needs, and treatment duration?

That “benefit vs. burden” discussion is exactly what patient partnership looks like in real life: it’s not one-size-fits-all.
It’s shared decision-making with clear tradeoffs on the table.

Precision Oncology: Not Just “Find a Mutation,” But “Fix the System”

Precision oncology depends on testingtumor profiling, sometimes germline testing, and consistent access to high-quality pathology and interpretation.
ASCO 2023 highlighted both the promise and the gaps: sophisticated therapies can’t help patients who never get the biomarker test that unlocks them.

This is where the 2023 conversation shifted from pure science to real-world implementation:

• Equitable access to molecular testing so targeted therapy isn’t a zip-code perk.
• Better trial participation so results apply to the real population, not a narrow slice of it.
• Clearer communication so patients understand what a biomarker result means (and what it doesn’t).

If ASCO 2023 had an unspoken subtitle, it might have been: “Precision medicine only works if the health system is precise, too.”

Immunotherapy, Evolved: Earlier Use, Smarter Combinations, Clearer Limits

Immunotherapy remains one of oncology’s defining innovations, but ASCO 2023 reflected a more mature phase of the field.
The excitement has shifted from “checkpoint inhibitors are amazing!” to “where do they help the most, and how do we use them safely?”

Key themes included:

• Perioperative immunotherapy (like KEYNOTE-671) to reduce recurrence after surgery in selected cancers.
• Combination strategies that aim to overcome resistancebalanced against added toxicity.
• Better patient selection so the people most likely to benefit get priority, and others avoid ineffective side effects.

In other words: immunotherapy is no longer “the new kid.” It’s a core tooland ASCO 2023 focused on using it with discipline.

Antibody-Drug Conjugates: “Smart Chemo” Keeps Expanding

Antibody-drug conjugates (ADCs) were a recurring buzzword in 2023. If you’ve never heard of ADCs, imagine a guided missile:
an antibody targets a marker on cancer cells and delivers a potent payload more directly than traditional chemotherapy.
That doesn’t mean side effects disappearbut it can shift the risk-benefit equation in meaningful ways.

ASCO 2023 discussions reflected a broader ADC trend: expanding beyond the first cancers where these drugs made their name.
There was also a strong undercurrent of “fine-tuning”: figuring out who benefits most, what biomarkers matter, and how to manage toxicities proactively.

Supportive Care and Symptom Science: The Research That Helps People Live Their Days

Not every breakthrough is a new drug. Some of the most patient-centered science at ASCO 2023 focused on managing symptoms and reducing long-term harm.
Two especially practical themes stood out:

1) Use patient-reported outcomes to guide real choices

Patient-reported outcomes (PROs) help capture what clinic notes often miss: the day-to-day reality of fatigue, bowel function,
neuropathy, sexual health, mood, and more. ASCO 2023 highlighted how PRO data can guide shared decisionsespecially when two
treatment strategies have similar efficacy.

2) Chemotherapy-induced peripheral neuropathy (CIPN) is not “just a nuisance”

Research presented at the meeting reinforced that neuropathy from taxanes can be persistent and quality-of-life limiting.
That matters because it pushes the field toward risk prediction, prevention strategies, and smarter drug selection and dosing.
Translation: the goal is not just “finish chemo,” but “finish chemo without losing function you need to live normally.”

Health Equity: A Scientific Priority, Not a Side Panel

ASCO 2023 didn’t treat health equity as optional.
Conversations about accessto screening, high-quality surgery, radiation, molecular testing, and clinical trialsshowed up alongside the biology.
The logic is straightforward: if we can map tumors at the molecular level, we should also be able to map where patients fall through cracks
and fix those gaps with the same seriousness.

A patient-centered oncology system asks hard questions:
Who is getting biomarker testing late (or not at all)? Who can’t travel for trials? Who is making decisions with incomplete information
because they didn’t get a clear explanation? ASCO 2023 kept returning to the idea that scientific progress and access progress must move together.

What Happens After ASCO: Turning Conference Data into Real-World Care

A healthy skepticism is part of good science. Not everything presented at ASCO becomes standard of care, and timing matters:
some studies are practice-changing immediately, some require longer follow-up, and some are signals that inspire new trials.

If you’re a patient or caregiver trying to make sense of “ASCO news,” here’s a useful filter:

• Was it a randomized phase III trial? That’s usually the strongest evidence for changing practice.
• Was it published in a peer-reviewed journal? Simultaneous publication is a good sign of maturity.
• Is it relevant to a specific biomarker or stage? Many “breakthroughs” are for a defined subgroup.
• Is the benefit meaningful for you? Ask about outcomes (survival, recurrence, symptoms), not just tumor shrinkage.

And the most important step: bring questions to your oncology team. They can interpret how a study applies to your diagnosis, stage,
biomarker profile, and personal priorities.

FAQs People Asked (and Still Ask) After ASCO 2023

Does “practice-changing” mean everyone should switch immediately?

Not automatically. “Practice-changing” usually means strong evidence supports a new approach for a defined group.
Your eligibility depends on staging details, tumor biology, and overall health.

How do patients access new treatments?

Some options are available through standard care (especially if approved and in guidelines). Others may be available through clinical trials,
expanded access programs, or after additional regulatory steps. Your care team can clarify what’s realistic now.

What if I feel overwhelmed by all the data?

Completely normal. Even oncologists triage this information.
A practical approach: focus on your cancer type, your stage, and whether you have specific biomarkers that open targeted options.

Real-World Experiences Around ASCO 2023: What It Felt Like (and What It Meant)

If you could bottle the emotional weather of ASCO 2023, it would be a mix of cautious optimism, jet lag, and the quiet intensity of people
who know the stakes are not theoretical. Many attendees describe the conference as a “city of cancer conversations” that runs on coffee,
poster sessions, and a shared urgency to turn data into timemore time for patients.

For clinicians, ASCO can feel like a high-speed update to the brain. You might walk into one session thinking,
“This is how we treat intermediate-risk rectal cancer,” and walk out realizing there’s now serious evidence that some patients who respond to
chemotherapy may be able to avoid radiationmeaning fewer long-term side effects without losing cancer control. The mood in those rooms is often
a blend of excitement and responsibility: excitement because the field is improving, and responsibility because “who qualifies” matters as much as
“what worked.”

For researchers, ASCO 2023 was a reminder that biology is only half the story. Precision oncology is dazzlingsequencing, biomarkers,
targeted drugsbut the hallway conversations kept circling back to implementation: Are patients getting tested on time? Are results interpreted correctly?
Are we enrolling diverse populations in trials so outcomes are trustworthy across communities? Many scientists talk about ASCO as the place where you can
feel a study’s real-world friction: the difference between what a trial proves and what the health system can actually deliver.

For patient advocates, the “partnering with patients” theme felt less like branding and more like a challenge. Advocates often describe
ASCO as a place where they push for plain language, meaningful endpoints, and quality-of-life measures that reflect real living. In 2023, patient-reported
outcomes were a recurring spotlight, which mattered because it validated something patients have said forever: “I am not a tumor measurement.”
Conversations about bowel function, neuropathy, fatigue, fertility, sexual health, and mental well-being weren’t treated as side notes; they were treated
as outcomes that shape lives.

For trainees and early-career oncology folks, ASCO can feel like drinking from a firehose while also trying to look calm in front of your heroes.
Many describe the poster hall as both inspiring and humbling: thousands of studies, each representing years of work, all competing for attention in the span of
an afternoon. But ASCO 2023’s biggest “aha” moments often weren’t flashy. They were the studies that made care gentler without making it weakerlike finding
ways to reduce treatment intensity for selected patients, or delaying chemotherapy and radiation when a targeted therapy might safely buy time.

And then there are the human moments that don’t show up in abstracts: clinicians swapping stories about how they explain biomarker testing to anxious
families; advocates reminding everyone that survivorship includes finances, work, and relationships; and researchers quietly celebrating because a curve on a
slide means someone, somewhere, will get a better chance. If ASCO 2023 had a collective takeaway, it might be this:
progress is realand the next phase of progress is making it usable, equitable, and aligned with what patients value most.

Conclusion

The 2023 ASCO Conference captured a modern oncology reality: breakthrough care isn’t only about new drugsit’s about smarter sequencing,
better selection, and fewer unnecessary harms. From de-escalation strategies in rectal cancer to targeted therapy that can delay more toxic brain tumor
treatments, and from perioperative immunotherapy to quality-of-life research powered by patient-reported outcomes, ASCO 2023 pushed the field toward
cancer care that is not just longer, but better.

If you’re following ASCO headlines as a patient or caregiver, focus on what’s most relevant to your situation: cancer type, stage, biomarker status,
and your personal priorities. Then bring that information to the people best equipped to apply ityour oncology team.